DB
MDGL icon

Danske Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

Danske Bank’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Hold
20
– – ﹤0.01% 808
2026
Q1 		$10.5K Sell
20
-180
-90% -$86K ﹤0.01% 799
2025
Q4 		$116K Buy
+200
New +$102K ﹤0.01% 752
2024
Q4 		– Sell
-500
Closed -$106K – 1549
2024
Q3 		$106K Buy
500
+400
+400% +$102K ﹤0.01% 1006
2024
Q2 		$28K Buy
+100
New +$23.8K ﹤0.01% 1032

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Danske Bank's MDGL Position: Q2 2026 in Review

Danske Bank held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 20 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #808.

Danske Bank first reported a position in MDGL in Q2 2024 and has held it in 5 quarters since. The position peaked at $116K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Danske Bank held 20 shares of Madrigal Pharmaceuticals worth $10.7K as of Q2 2026.
  • Danske Bank left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #808 holding.
  • Danske Bank first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Danske Bank's Madrigal Pharmaceuticals position peaked at $116K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.